Hypothyroidism after treatment of metastatic neuroblastoma

Pediatric Blood and Cancer

Volumn 55, Issue 4, 2010, Pages 768-768

  Lackner, Herwig ^a   Urban, Christian ^a   Sovinz, Petra ^a   Nebl, Andrea ^a   Schmidt, Sandrin ^a   Benesch, Martin ^a   Schwinger, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; MONOCLONAL ANTIBODY I 131; POTASSIUM IODIDE; THYROTROPIN; (3 IODOBENZYL)GUANIDINE; RADIOACTIVE IODINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL ASSESSMENT; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; HYPOTHYROIDISM; LETTER; METASTASIS; NEUROBLASTOMA; PRIORITY JOURNAL; THYROID FUNCTION; FEMALE; MALE; NOTE; RADIOIMMUNOTHERAPY;

3-IODOBENZYLGUANIDINE; FEMALE; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; MALE; NEUROBLASTOMA; RADIOIMMUNOTHERAPY;

EID: 77957034673     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22593     Document Type: Letter

References (3)

1. 131I-monoclonal antibody treatment of neuroblastoma. Pediatr Blood Cancer 2010; 10.1002/pbc.22452.
2. Santen HM, Kraker J, Vijlder JJ, et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodbenzylguanidine treatment in children with neuroblastoma. Cancer 2002; 94: 2081-2088.
3. Sanders JE, Hoffmeister PA, Woolfrey AE, et al. Thyroid function following hematopoetic cell transplantation in children: 30 years' experience. Blood 2009; 113: 306-308.